Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle
Open Access

Physiological Temperature Changes Fine-Tune β2- Adrenergic Receptor-Induced Cytosolic cAMP Accumulation

Dennis Faro, Ingrid Boekhoff, Thomas Gudermann and Andreas Breit
Molecular Pharmacology September 2021, 100 (3) 203-216; DOI: https://doi.org/10.1124/molpharm.121.000309
Dennis Faro
Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, München, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid Boekhoff
Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, München, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Gudermann
Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, München, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Breit
Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, München, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Temperature sensitivity of BMAL, CREB, STAT or FOXO activity in mHypoA-2/10 cells. Basal reporter activity of BMAL1- (A), FOXO- (B), STAT- (C and E), or CREB-dependent (D and F) luciferase reporter was detected after 2, 4, or 8 hours at 36, 37, or 38°C. Data were normalized by setting data obtained at 37°C to 100%. Blue symbols present data obtained at 36°C, red symbols data at 38°C. Results are expressed as the mean ± S.D. of 6 independent experiments performed in triplicates. Asterisks indicate significant differences between 36 and 38°C using two-way ANOVA with Ṧidák’s post hoc test. Hash signs indicate significant differences to 37°C (set to 100%) using one-sample t test. In (E), cells were first exposed to 36 or 38°C for 4 hours, then stimulated with IFNγ (100 nM) and in (F) with 10 µM NE or 10 µM FSK for an additional 4 hours and x-fold over basal calculated. Results are expressed as the mean ± S.D. of 4 independent experiments performed in quadruplicates. Differences between 36 and 38°C were analyzed using two-ANOVA with Ṧidák’s post hoc test.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    mHypoA-2/10 cells express β2-AR and β3-AR. In (A) reads per kilobase of transcript per million reads mapped values for α1-, α2- and β-AR are shown as the mean ± S.D. RNAs from six distinct cell pools were used. In (B), aequorin expressing cells were stimulated with the indicated ligand by automatic injection at time point 5 second. In (C) saturation-binding experiments with total membrane fractions (20 µg) are shown. 125I-CYP (3.125–400 pM) was either used alone (total binding) or together with 10 µM propranolol (unspecific binding). Receptor-bound 125I-CYP was calculated by subtracting unspecific from total binding. Results of 3 independent experiments performed in triplicates are expressed as the mean ± S.D. Data were fitted using a nonlinear fit (one-site specific binding). In (D to E) data using cells stably expressing the CREB-dependent luciferase reporter are shown. In (D) serum-starved cells were stimulated or not for 4 hours at 37°C with either NE (10 µM), ISO (10 µM), or Sal (100 nM). Cells were then lysed, luciferase activity determined, and x-fold over basal calculated. Data of 5 independent experiments performed in quadruplicates are expressed as the mean ± S.D. In (E), cells were preincubated for 30 minutes with 10 µM of the PKC inhibitors BIM-X or (3-[1-[3-(dimethylamino)propyl]-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione), the PKA inhibitor KT-5720, or the exchange factor directly activated by cAMP inhibitor ESI-09. In (F), serum-starved cells were stimulated for 4 hours at 37°C with either NE (10 µM) alone or together with increasing concentrations of ICI118551, SR59230A, or phentholamine. Cells were then lysed, luciferase activity determined, and data obtained with NE alone set to 100%. All other signals were calculated as percentage. Data of 6 independent experiments performed in triplicates were expressed as the mean ± S.D. and analyzed by a nonlinear fit (two-site fit logIC50).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Competition binding with membranes from mHypoA-2/10 cells at distinct temperatures. Competition-binding experiments with total membrane fractions (20 µg) and 125I-CYP (75 pM) performed for 1 hour at 36°C (blue symbols) or at 38°C (red symbols) are shown. In (A) increasing concentrations of NE and in (B–D) of Sal were used to detect specific binding. The total 125I-CYP binding in the absence of any agonist was set to 100%, and all other values calculated as percentage. In (C) and (D), membranes were preincubated or not with 10 µM of Gpp(NH)p. Data of 3 (A and B) or 4 (C and D) independent experiments performed in triplicates were expressed as the mean ± S.D and fitted using a nonlinear fit (one-site logIC50 in A or two-site fit logIC50 in B to D). Parameters of the binding curves are given in Table 1.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    NE- or Sal-induced cAMP accumulation is enhanced at 36°C. cAMP accumulation was determined for 1 hour with 1 mM IBMX alone or with NE, FSK (both 10 µM), or Sal (100 nM) in A to D. In (E) increasing concentrations of NE were used. Blue bars present data obtained at 36°C, red bars data at 38°C, and black bars at 37°C. In (A and E) data are presented as the ratio cAMP/cAMP + ATP, in (B) as x-fold over basal in (C) data obtained at 38°C and in (D) at 37°C were set to 100%. Data of 7 (A–C), 3 (D), or 4 (E) independent experiments performed in triplicates were expressed as the mean ± S.D. Data shown in (A–C) are the same. Two-way ANOVA followed by Ṧidák’s post hoc test was used to determine statistical differences. In (E), data were fitted using a nonlinear fit (logagonist versus response variable slope; four parameters)

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    NE-induced cytosolic cAMP accumulation and efflux. In (A), cytosolic cAMP accumulation for 10, 20, 40, or 60 minutes with 1 mM IBMX alone or with 10 µM NE was detected at 37°C. In (B), cAMP levels in the supernatants of the same samples are shown. In (C), cAMP levels in the supernatants of cells stimulated with 1 mM IBMX and 10 µM NE are shown in the presence or not of 100 µM indomethacin. In (D), data from (A) and (B) were compiled. Data of 4 independent experiments performed in triplicates were expressed as the mean ± S.D. One-way ANOVA followed by Tukey’s post hoc test was used in (A, B, and D) and unpaired t test in (C) to determine statistical differences.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    NE-induced cytosolic cAMP accumulation and efflux are temperature-sensitive. Cytosolic cAMP accumulation (A) and efflux (B) induced by 10 µM NE in the presence of 1 mM IBMX was measured for 20 and 60 minutes at 36 or 38°C. In (C), rEC-cAMP at 20 or 60 minutes were calculated. In (D), data from (A) and (B) were compiled. Blue bars present data obtained at 36°C, red bars data at 38°C. Data of 4 independent experiments performed in triplicates were expressed as the mean ± S.D. Two-way ANOVA followed by Ṧidák’s post hoc test (A–C) or Tukey’s post hoc test (D) was used to determine statistical differences.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    NE-induced 3H-cAMP degradation is enhanced at 38°C. In (A), 3H-cAMP degradation in homogenates from unstimulated cells was measured for 10, 20, 40, or 60 minutes with or without 1 mM IBMX at 37°C. As a control (input), the same amount of 3H-cAMP was incubated without homogenates and also purified. No statistical differences between homogenates with IBMX and the input control were observed (data not shown). In (B and C), 3H-cAMP degradation in homogenates of cells treated with 10 µM NE for 30 minutes at 37°C without IBMX was measured for 20 minutes at 36 or 38°C. Blue bars present data obtained at 36°C, red bars data at 38°C. In (B), raw data are shown as 3H-cAMP in decays per minute. In (C), 3H-cAMP degradation was calculated as percentage of the corresponding input control. 7 independent experiments performed in triplicates were expressed as the mean ± S.D. Two-way ANOVA followed by Ṧidák’s post hoc test was used in (B) and two-tailed t test in (C) to determine statistical differences.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Basal and NE-induced thyreoliberin promoter activity is increased at 36°C. Thyreoliberin promoter activity was monitored using mHypoA-2/10 cells stably expressing a luciferase promoter construct encoding the rat thyreoliberin promoter. Basal and NE (10 µM)-induced promoter activity was measured for 1, 2, 3, and 4 hours at 36°C (blue bars) or 38°C (red bars). In (A), basal reporter activity is given in RLU. In (B), x-fold over basal values of NE-stimulated cells are provided. Data of 4 independent experiments performed in triplicates were expressed as the mean ± S.D. Two-way ANOVA followed by Ṧidák’s post hoc test was used to determine statistical differences.

  • Fig. 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 9.

    BAY60-6583 but not BK-induced CREB activation is enhanced at 36°C. In (A, B, and D), data using cells stably expressing the CREB-dependent luciferase reporter are shown. In (C), ligand-induced cytosolic cAMP accumulation is given as x-fold of basal after stimulation of cells with BAY60-6583 or BK (both 1 µM) at 37°C for 30 minutes. Data of 3 independent experiments performed in triplicates are compiled as the mean ± SD and two-tailed t test performed to determine statistical differences. In (A), CREB reporter–expressing mHypoA-2/10 cells were stimulated for 4 hours at 37°C with BAY60-6583 or BK (both 1 µM). Data of 3 independent experiments performed in triplicates are compiled as the mean ± SD and two-tailed t test performed todetermine statistical differences. In (C), cells were preincubated with the PKC inhibitors BIM-X or Gö6983 (both 10 µM) and the stimulated with BK (1 µM) for 4 hours at 37°C. Data of 3 independent experiments performed in triplicates are compiled as the mean ± SD, and one-way ANOVA followed by Ṧidák’s post hoc test used to determine statistical differences. In (D), cells were either incubated for 4 hours at 36 or 38°C and then for additional 4 hours stimulated with BAY60-6583 or BK (both 1 µM). Bars in red indicate data obtained at 38°C, bars in blue at 36°C. Data obtained at 38°C were set to 100%. Two-tailed t test was performed to determine statistical differences.

  • Fig. 10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 10.

    NE- or Sal-induced cAMP accumulation is enhanced at 36°C in various cell lines. cAMP accumulation was measured after stimulation of cells with NE (10 µM) at 37°C (A) or at 36 and 38°C with NE (10 µM) or Sal (100 nM) in (B–E). In (A), data of 5 independent experiments performed in quadruplicates are compiled as the mean ± SD. In (B), mHypoA-2/12 cells, in (C), H1299 cells, in (D), primary HBSMCs, and in (E), data of HaCaT cells are shown. Bars in red indicate data obtained at 38°C, bars in blue at 36°C. Data obtained at 38°C were set to 100%. Two-way ANOVA followed by Ṧidak‘s post hoc test was used to determine statistical differences.

  • Fig. 11.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 11.

    Increased temperature decreases NE-induced cytosolic cAMP accumulation by enhancing PDE activity and cAMP efflux. A model based on the data shown in Fig. 6 is depicted. Assuming that NE-induced cAMP production in mHypoA-2/10 cells is temperature-insensitive, we set the amount of original produced cAMP to 100%. At 36°C (blue path), no cAMP is degraded in the presence of the PDE inhibitor IBMX (1 mM). Thus, the entire cAMP pool is available for cAMP transporters. 52% of this pool is exported and 48% remains in the cell, resulting in a rEC-cAMP of 1.08. At 38°C (red path), around 27% of the produced cAMP is degraded, 44% exported and 29% remains in the cytosol. Thus, resulting in a rEC-cAMP of 1.52.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Competition-binding data of 125I-CYP (75 pM) and Sal with 10 µM Gpp(NH)p. Original binding curves are shown in Fig. 3, C and D

    36°C38°C
    pM%pM%
    IC50fractionIC50fraction
    Control

    Ratio high-affinityto low-affinity state
    High-affinity state3.4 ± 1.439 ± 25.6 ± 1.538 ± 2
    Low-affinity state7,713 ± 65761 ± 29,838 ± 1,45062 ± 2
    0.640.62
    Gpp(NH)p

    Ratio high-affinityto low-affinity state
    High-affinity state13 ± 2.422 ± 36.3 ± 2.824 ± 3
    Low-affinity state9,398 ± 58378 ± 312,830 ± 77576 ± 3
    0.280.31

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • Supplemental Figure  -

      Supplemental Figure 1 - The selective PDE-8 blocker PF04957325 has no effect on NE-induced cAMP accumulation in mHypoA-2/10 cells.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 100 (3)
Molecular Pharmacology
Vol. 100, Issue 3
1 Sep 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Physiological Temperature Changes Fine-Tune β2- Adrenergic Receptor-Induced Cytosolic cAMP Accumulation
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Enhanced Norepinephrine-Induced cAMP Accumulation at 36°C

Dennis Faro, Ingrid Boekhoff, Thomas Gudermann and Andreas Breit
Molecular Pharmacology September 1, 2021, 100 (3) 203-216; DOI: https://doi.org/10.1124/molpharm.121.000309

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Enhanced Norepinephrine-Induced cAMP Accumulation at 36°C

Dennis Faro, Ingrid Boekhoff, Thomas Gudermann and Andreas Breit
Molecular Pharmacology September 1, 2021, 100 (3) 203-216; DOI: https://doi.org/10.1124/molpharm.121.000309
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics